Top Markets
#1 Black Phoenix Black Phoenix +826.64%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.17%
#3 Beam Beam +24.88%
#4 Bless Bless +21.52%
#5 Tutorial Tutorial +21.07%
#6 SAFEcoin SAFEcoin +20.45%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +19.37%
#8 Magma Finance Magma Finance +17.16%
#9 THORChain THORChain +17.07%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +15.57%
Coin of the day
Black Phoenix Black Phoenix
Setări
Limbă
ROMâNă
Monedă
USD
Temă
China Resources Double-Crane Pharmaceutical Co.,Ltd. China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062
Rang în acțiuni #5801
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its... China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.
Preț acțiune
$2.34
Capitalizare de piață
$2.43B
Schimbare (1 zi)
-0.37%
Schimbare (1 an)
-14.62%
Țară
CN
Tranzacționează China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)

Categorie

Healthcare
Marja operațională pentru China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)
Marja operațională la 2026 TTM: 0.00%
Conform celor mai recente rapoarte financiare și prețului acțiunilor China Resources Double-Crane Pharmaceutical Co.,Ltd., marja operațională curentă (TTM) este 0.00%. La finalul anului 2026, compania avea o marjă operațională de 0.00%.
Istoricul marjei operaționale pentru China Resources Double-Crane Pharmaceutical Co.,Ltd. din 2026 până în 2026
Marja operațională la sfârșitul fiecărui an
An Marja Operațională Schimbă
Nu sunt suficiente date pentru perioada selectată.
Marja operațională pentru companii similare sau concurente
Companie Marja Operațională Diferență în marja operațională Țara
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
0.00% -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
0.00% -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
0.00% -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
0.00% -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
22.93% -
IN
Ce este marja operațională a unei companii?
Marja operațională este un indicator esențial pentru evaluarea profitabilității unei companii. Marjele operaționale mai mari sunt de obicei mai bune, deoarece arată că o companie poate vinde produsele sau serviciile sale la prețuri mult mai mari decât costurile de producție. Marja operațională se calculează împărțind profitul companiei la venitul său.